TABLE 1.
Vaccine Doses Administered in the Vaccine Safety Datalink to Children Aged 6 Months to <5 Years, June 18, 20 22 Through March 18, 2023
| Characteristic | Number of Doses Administered | |
|---|---|---|
| Pfizer-BioNTech,a n (%) | Moderna,b n (%) | |
| Total | 135 005 | 112 006 |
| Dose 1 | 60 134 (45) | 59 872 (53) |
| Dose 2 | 50 903 (38) | 52 134 (47) |
| Dose 3 | 23 968 (18) | NA |
| Sex | ||
| Female | 66 343 (49) | 55 228 (49) |
| Male | 68 662 (51) | 56 778 (51) |
| Age | ||
| 6 mo–<1 y | 17 081 (13) | 16 566 (15) |
| 1–<2 y | 25 979 (19) | 22 062 (20) |
| 2–<3 y | 27 791 (21) | 22 510 (20) |
| 3–<4 y | 31 218 (23) | 22 708 (20) |
| 4–<5 y | 32 936 (24) | 23 428 (21) |
| 5–<6 y | NA | 4732 (4) |
| Race and ethnicityc | ||
| American Indian/Alaskan Native | 305 (<1) | 225 (<1) |
| Asian | 34 528 (26) | 26 903 (24) |
| Black, Non-Hispanic | 4260 (3) | 3105 (3) |
| Hispanic/Latino | 26 543 (20) | 19 482 (17) |
| Native Hawaiian/Pacific Islander | 817 (<1) | 498 (<1) |
| White, non-Hispanic | 42 158 (31) | 39 944 (36) |
| Multiple or other | 8022 (6) | 5940 (5) |
| Unknown | 18 372 (14) | 15 909 (14) |
NA, not applicable.
The Pfizer-BioNTech vaccine is authorized for use in children 6 mo to <5 y of age as a 3-dose series with dose 1 and dose 2 given 21 d apart, and dose 3 given 2 mo following dose 2. Only monovalent dose 3ʹs are included in this surveillance; bivalent doses are monitored in separate VSD safety surveillance.
The Moderna vaccine is authorized for use in children 6 mo to <6 y of age as a 2-dose series with dose 1 and dose 2 given 28 d apart.
VSD sites routinely create dynamic files that are updated weekly and contain information on demographics (including race and ethnicity in fixed categories based on self-reported data from the participating health plans).